Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chunling Liu

Showing results (161-170 of 197) with videos related to

Pageof 20
Sort By:
European Radiology|June 15, 2022
MRI characteristics of breast edema for assessing axillary lymph node burden in early-stage breast cancer: a retrospective bicentric studyZeyan Xu, Yingying Ding, Ke Zhao, et al.
Clinical and Experimental Dermatology|April 15, 2024
Supramolecular salicylic acid combined with niacinamide in chloasma: a randomized controlled trialYing Xiong, Xian Jiang, Wei Lai, et al.
Plant Physiology and Biochemistry : PPB|February 14, 2025
Zinc promotes nitrogen uptake and plant growth by regulating the antioxidant system and carbon-nitrogen metabolism under drought condition in apple plantsYafei Guan, Lei Lu, Jingquan Liu, et al.
The Lancet. Oncology|January 15, 2026
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trialLiang Zhang, Xiqin Zhang, Lin Wu, et al.
BMJ Oncology|February 25, 2026
SAFFRON-301: a randomised phase III study of sitravatinib in combination with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancerQing Zhou, Bo Gao, Jie Hu, et al.
The Lancet. Respiratory Medicine|March 29, 2021
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label studyYuankai Shi, Xingsheng Hu, Shucai Zhang, et al.
Eclinicalmedicine|June 30, 2025
Development and validation of an MRI spatiotemporal interaction model for early noninvasive prediction of neoadjuvant chemotherapy response in breast cancer: a multicentre studyWenjie Tang, Chen Jin, Qingcong Kong, et al.
The Lancet. Respiratory Medicine|June 6, 2022
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 studyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 6, 2022
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG StudyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
The Lancet. Oncology|June 15, 2026
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trialZiming Li, Jie Hu, Jianhua Chen, et al.
Pageof 20

Showing results (161-170 of 197) with videos related to

Sort By:
Pageof 20
European Radiology|June 15, 2022
MRI characteristics of breast edema for assessing axillary lymph node burden in early-stage breast cancer: a retrospective bicentric studyZeyan Xu, Yingying Ding, Ke Zhao, et al.
Clinical and Experimental Dermatology|April 15, 2024
Supramolecular salicylic acid combined with niacinamide in chloasma: a randomized controlled trialYing Xiong, Xian Jiang, Wei Lai, et al.
Plant Physiology and Biochemistry : PPB|February 14, 2025
Zinc promotes nitrogen uptake and plant growth by regulating the antioxidant system and carbon-nitrogen metabolism under drought condition in apple plantsYafei Guan, Lei Lu, Jingquan Liu, et al.
The Lancet. Oncology|January 15, 2026
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trialLiang Zhang, Xiqin Zhang, Lin Wu, et al.
BMJ Oncology|February 25, 2026
SAFFRON-301: a randomised phase III study of sitravatinib in combination with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancerQing Zhou, Bo Gao, Jie Hu, et al.
The Lancet. Respiratory Medicine|March 29, 2021
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label studyYuankai Shi, Xingsheng Hu, Shucai Zhang, et al.
Eclinicalmedicine|June 30, 2025
Development and validation of an MRI spatiotemporal interaction model for early noninvasive prediction of neoadjuvant chemotherapy response in breast cancer: a multicentre studyWenjie Tang, Chen Jin, Qingcong Kong, et al.
The Lancet. Respiratory Medicine|June 6, 2022
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 studyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 6, 2022
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG StudyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
The Lancet. Oncology|June 15, 2026
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trialZiming Li, Jie Hu, Jianhua Chen, et al.
Pageof 20